{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-028373","form_type":"8-K","ticker":"NTLA","cik":"0001652130","company_name":"Intellia Therapeutics, Inc.","filed_at":"2025-02-27T23:59:59+00:00","discovered_at":"2026-05-14T18:03:04.316549+00:00","generated_at":"2026-05-26T02:02:30.455103+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Intellia Q4 net loss $128.9M; cuts workforce 27%, ends NTLA-3001","bullets":["Q4 2024 net loss $128.9M vs $132.2M prior year; revenue $12.9M.","Ended 2024 with $861.7M cash; funding into first half of 2027.","Workforce reduction of ~27% in 2025; expects $8M severance charges.","Phase 3 HAELO (NTLA-2002) dosed first patient; BLA submission planned H2 2026.","Enrollment in MAGNITUDE (nex-z for ATTR-CM) ahead of projections, >550 patients by year end."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-028373","json":"https://secwatch.observer/filing/0000950170-25-028373.json","markdown":"https://secwatch.observer/filing/0000950170-25-028373.md","text":"https://secwatch.observer/filing/0000950170-25-028373.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1652130/000095017025028373/0000950170-25-028373-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1652130/000095017025028373/ntla-20250227.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-26T02:02:30.455103+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}